Nephrol Dial Transplant (2001) 16: 1790-1798
© 2001 European Renal Association-European Dialysis and Transplant Association
Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis
Departments of 1Nephrology, and 2 Pathology and 3 Endocrinology, Hospital Universitario ‘12 de Octubre’, Madrid, Spain
Background. Several cases of obesity-associated focal segmental glomerulosclerosis (OB-FSG) have been reported but little is known about the clinico-pathological features of this entity and its long-term outcomers.
Methods. We studied 15 obese patients (BMI 35±5.2 kg/m2) with biopsy-proven FSG. They were compared with a control group of 15 non-obese patients with idiopathic FSG (I-FSG).
Results. Mean proteinuria at the time of renal biopsy was 3.1±2 g/24 h in OB-FSG; it reached the nephrotic range (
3.5 g/24 h) during follow-up in 12 patients (80%), but none of them had oedema, hypoproteinaemia, or hypoalbuminaemia. Proteinuria was more marked amongst I-FSG (6.5±4.2 g/24 h) and most of them developed oedema and biochemical nephrotic syndrome. Glomerulomegaly was observed in all renal biopsies from OB-FSG patients (mean glomerular diameter 256±24 µm in OB-FSG vs 199±26 µm in I-FSG, P<0.001). Twelve OB-FSG patients (80%) were treated with ACE inhibitors (ACEI) and proteinuria significantly decreased within the first 6 months of treatment but showed a later increase. None of the obese patients achieved a sustained weight loss. Seven (46%) patients with OB-FSG experienced a progressive renal insufficiency and five of them started intermittent dialysis. Kaplan–Meier estimated probabilities of renal survival after 5 and 10 years were 77 and 51%, respectively, in OB-FSG patients, and 52 and 30% in I-FSG (P<0.05). The risk of developing progressive renal failure among OB-FSG patients was statistically correlated with serum creatinine and creatinine clearance at presentation.
Conclusions. OB-FSG indicates a poor prognosis with almost one-half of patients developing advanced renal failure. Knowledge of the clinico-pathological features of this entity (obesity, FSG lesions with glomerulomegaly, absence of nephrotic syndrome despite nephrotic-range proteinuria) should be helpful in establishing an accurate and early diagnosis.
Keywords: ACE inhibitors; focal and segmental glomerulosclerosis; obesity; progression of renal insufficiency
Correspondence and offprint requests to: Dr Manuel Praga, Servicio de Nefrología, Hospital 12 de Octubre, Carretera de Andalucia, Km 5, 400, E-28041 Madrid, Spain.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. S. Goumenos, B. Kawar, M. El Nahas, S. Conti, B. Wagner, C. Spyropoulos, J. G. Vlachojannis, A. Benigni, and F. Kalfarentzos Early histological changes in the kidney of people with morbid obesity Nephrol. Dial. Transplant., July 13, 2009; (2009) gfp329v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Kuhlmann, F. G. Bormann, and H. F. Becker Obstructive sleep apnoea: clinical signs, diagnosis and treatment Nephrol. Dial. Transplant., January 1, 2009; 24(1): 8 - 14. [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Griffin, H. Kramer, and A. K. Bidani Adverse renal consequences of obesity Am J Physiol Renal Physiol, April 1, 2008; 294(4): F685 - F696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Ar. Mani, J. Radhakrishnan, H. Wang, Al. Mani, M.A. Mani, C. Nelson-Williams, K.S. Carew, S. Mane, H. Najmabadi, D. Wu, et al. Metabolic Syndrome--What We Know and What We Don't Know: LPR6 Mutation in a Family with Early Coronary Disease and Metabolic Risk Factors. Science 315: 1278-1282, 2007 J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1619 - 1623. [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Wahba and R. H. Mak Obesity and Obesity-Initiated Metabolic Syndrome: Mechanistic Links to Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 550 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Praga Synergy of low nephron number and obesity: a new focus on hyperfiltration nephropathy Nephrol. Dial. Transplant., December 1, 2005; 20(12): 2594 - 2597. [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Ahmed, N. D.L. Fisher, R. Stevanovic, and N. K. Hollenberg Body Mass Index and Angiotensin-Dependent Control of the Renal Circulation in Healthy Humans Hypertension, December 1, 2005; 46(6): 1316 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Samuel, W. E. Hoy, R. Douglas-Denton, M. D. Hughson, and J. F. Bertram Determinants of Glomerular Volume in Different Cortical Zones of the Human Kidney J. Am. Soc. Nephrol., October 1, 2005; 16(10): 3102 - 3109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Bagby Obesity-Initiated Metabolic Syndrome and the Kidney: A Recipe for Chronic Kidney Disease? J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2775 - 2791. [Full Text] [PDF]
|
|
|
|
|
|
G. Wolf After all those fat years: renal consequences of obesity Nephrol. Dial. Transplant., December 1, 2003; 18(12): 2471 - 2474. [Full Text] [PDF]
|
|
|
|
 |
|
 G. D Laverman, D. de Zeeuw, and G. Navis Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy? Journal of Renin-Angiotensin-Aldosterone System, December 1, 2002; 3(4): 205 - 213. [Abstract] [PDF]
|
|
|
|
|
|
M. Praga Obesity--a neglected culprit in renal disease Nephrol. Dial. Transplant., July 1, 2002; 17(7): 1157 - 1159. [Full Text] [PDF]
|
|